The expression levels of the anti-inflammatory gene NFKB1A, an inhibitor of the pro-inflammatory transcription factor NFKB1, were higher in severe COVID-19 patients (1.65 [0.14-4.29]) compared to the control group (0.98 [0.22-2.55]). The gene discussed is NFKB1; the disease is COVID-19.